Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of a Novel Aqueous Humor-Based Multiplex Assay for Uveal Melanoma Metastatic Risk Prediction

Award Number: R41CA291243
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/05/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

Development of a Novel Aqueous Humor-Based Multiplex Assay for Uveal Melanoma Metastatic Risk Prediction - Project Summary Uveal melanoma (UM) is a prevalent intraocular cancer, with approximately 3,000 new cases annually and an estimated total of 60,000-70,000 affected individuals in the US. This malignancy poses a distressing reality as around 50% of patients develop metastatic diseases within 5 years, leading to devastating consequences for patients and healthcare providers. Current methods for predicting metastasis risk rely on invasive needle biopsies based on gene expression profiles (GEP), which are performed once and can cause discomfort and complications. The urgent need to address this challenge calls for the development of an effective and least invasive prognostic tool that can accurately predict metastatic risk, enhance safety, and guide treatment decisions worldwide, thereby offering better surveillance for patients with reduced costs and alleviating their concerns. To tackle this challenge, we've established a novel approach for predicting metastasis risk using proteomic analysis of aqueous humor (AH), the clear fluid of the front chamber from eyes. AH paracentesis, a safe procedure routinely performed in ophthalmology practice for decades, enabled the identification of differentially expressed proteins in AH samples. With this STTR Phase 1 application, we aim to develop a fit-for-purpose test based on our innovation, aiming to provide an easy-to-use pre-clinical test that utilizes safely accessible AH-based protein biomarkers, ultimately improving prediction accuracy and informing patient care.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	OLMEDA BIOSCIENCES LLC	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Detection and Diagnosis Research	000	1	11/17/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $55,000 )
2025	2025	OLMEDA BIOSCIENCES LLC	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Detection and Diagnosis Research	000	1	5/23/2025	SUPPLEMENT FOR EXPANSION	$55,000
														Subtotal = $55,000

Issue Date FY: 2024 ( Subtotal = $396,161 )
2024	2024	OLMEDA BIOSCIENCES LLC	10966 VIA FRONTERA	SAN DIEGO	CA	92127	SAN DIEGO	USA	Cancer Detection and Diagnosis Research	000	1	9/13/2024	NEW	$396,161
														Subtotal = $396,161

Grand Total All Awards = $451,161

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a Novel Aqueous Humor-Based Multiplex Assay for Uveal Melanoma Metastatic Risk Prediction

Award Number: R41CA291243

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/05/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer